Generic Entresto ( Sacubitril/Valsartan )

Buy Generic Entresto (Sacubitril/Valsartan) without prescription in Canada

At our Canadian pharmacy, you can purchase Entresto (sacubitril/valsartan) 97 mg/103 mg without a prescription, with discreet and anonymous packaging delivered within 5-14 days across Canada. Entresto is a combination of a neprilysin inhibitor and an angiotensin II receptor blocker, used to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with chronic heart failure and reduced ejection fraction. The medication is typically taken twice daily. Would you like to try Entresto without a prescription?

Common use Entresto

Entresto contains sacubitril, which inhibits neprilysin, and valsartan, which blocks angiotensin II receptors. Together they increase levels of natriuretic peptides while blocking the harmful effects of angiotensin II. This dual action reduces the strain on the failing heart, promotes vasodilation, and decreases fluid retention. The drug is indicated for symptomatic heart failure with reduced ejection fraction, usually defined as left ventricular ejection fraction below 40 percent. In the PARADIGM-HF trial, Entresto reduced cardiovascular death and heart failure hospitalizations compared with enalapril. The benefit is seen across a broad range of patients, including those with mild to moderate symptoms. The medication does not cure heart failure, but it slows disease progression and improves quality of life.

Basic Entresto Information

INN (International Nonproprietary Name): Sacubitril / Valsartan
Brand names available in Canada: Entresto (no generics currently available)
ATC Code: C09DX04
Forms and dosages: Film-coated tablets (24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg)
Manufacturers in Canada: Novartis Pharmaceuticals Canada Inc.
Registration status in Canada: Approved by Health Canada (DIN 02456693 for 97/103 mg)
OTC / Rx classification: Prescription only (Rx) – not legally sold over-the-counter in Canadian pharmacies

Dosage and direction

The recommended starting dose of Entresto is 49 mg/51 mg taken orally twice daily. After two to four weeks, the dose is doubled to 97 mg/103 mg twice daily, as tolerated. Patients currently taking an ACE inhibitor or angiotensin receptor blocker should stop that medication for 36 hours before starting Entresto to avoid angioedema. The tablets can be taken with or without food. Swallow them whole with water. If you have moderate kidney impairment or are elderly, your doctor may start with the lower dose and adjust more slowly. The goal is to reach the target dose of 97 mg/103 mg twice daily, but some patients remain on lower doses if blood pressure or kidney function becomes a concern. Do not stop Entresto suddenly, because heart failure symptoms may worsen.

Precautions

Entresto can cause symptomatic hypotension, especially in patients who are volume-depleted or taking high doses of diuretics. Dizziness and lightheadedness are common early in treatment. The medication may worsen kidney function, so serum creatinine and potassium should be checked regularly. Hyperkalemia is a known risk, particularly in patients with diabetes, kidney disease, or those taking potassium supplements. Angioedema, including swelling of the face, lips, tongue, or throat, has been reported and requires immediate discontinuation and emergency care. Entresto should not be used in pregnancy because it can cause fetal harm or death. If you become pregnant, stop the drug and contact your doctor immediately. Tell your doctor if you have a history of angioedema, liver disease, or bilateral renal artery stenosis. Alcohol may worsen hypotension and should be limited.

Contraindications

Entresto is contraindicated in patients with known hypersensitivity to sacubitril, valsartan, or any component of the tablet. It should not be used in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy. Concomitant use with ACE inhibitors is contraindicated, and Entresto must not be started until at least 36 hours after discontinuing an ACE inhibitor. The drug is contraindicated during pregnancy and in women who may become pregnant. It should not be used in patients with hereditary or idiopathic angioedema. Entresto is contraindicated in patients with severe hepatic impairment. It should not be used in children because safety and efficacy have not been established. Patients with diabetes taking aliskiren should not use Entresto due to increased risk of adverse outcomes.

Side effects

The most common side effects of Entresto are hypotension, hyperkalemia, cough, dizziness, and kidney impairment. Less frequent adverse effects include headache, fatigue, diarrhea, and nausea. Orthostatic hypotension may occur when rising from a seated or lying position. Hyperkalemia is more likely in patients with diabetes or kidney disease and may require dose adjustment or discontinuation. Angioedema is rare but potentially life-threatening, presenting as swelling of the face, lips, tongue, or airway. If this occurs, seek emergency medical attention. Some patients experience a persistent dry cough, though this is less frequent than with ACE inhibitors. Kidney function should be monitored, as creatinine elevations are common early in treatment. Most side effects diminish after the first weeks, but any concerning symptom should be reported to your doctor.

Drug interaction

Entresto should not be combined with ACE inhibitors, as this increases the risk of angioedema. A 36-hour washout period is required when switching from an ACE inhibitor. Concomitant use with aliskiren is not recommended in patients with diabetes. Potassium-sparing diuretics such as spironolactone, eplerenone, or amiloride may increase hyperkalemia risk. Potassium supplements and salt substitutes containing potassium should be used with caution. NSAIDs may reduce the antihypertensive effect and worsen kidney function. Lithium levels may rise, requiring monitoring. Rifampin and other strong CYP3A4 inducers may reduce sacubitril exposure. Tell your doctor about all medications you take, including over-the-counter products and supplements.

Missed dose

If you miss a dose of Entresto, take it as soon as you remember. If it is close to your next scheduled dose, skip the missed one and continue with your regular schedule. Do not take two doses at the same time. Missing an occasional dose is not usually dangerous, but try to take the medication consistently to keep heart failure stable.

Overdose

Overdose with Entresto is likely to cause severe hypotension, dizziness, and possibly acute kidney injury. There is no specific antidote. Treatment includes intravenous fluids, placing the patient in a supine position, and supportive care. Hemodialysis is not effective in removing valsartan because it is highly protein-bound. If you suspect an overdose, contact a poison control centre or go to an emergency department immediately. Do not attempt to manage the situation at home.

Storage

Store Entresto tablets at room temperature between 15 and 30 degrees Celsius (59 and 86 degrees Fahrenheit). Keep the tablets in their original package to protect from moisture. Do not store in the bathroom or near a sink. Keep out of sight and reach of children and pets. Discard any unused tablets after the expiry date on the packaging. Do not flush medications down the toilet unless instructed to do so.

Disclaimer

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.